🇺🇸 bolus+infusion in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Aphasia — 1 report (12.5%)
2. Complex Partial Seizures — 1 report (12.5%)
3. Hypotension — 1 report (12.5%)
4. Infection — 1 report (12.5%)
5. Neoplasm Progression — 1 report (12.5%)
6. Prostate Cancer — 1 report (12.5%)
7. Pseudomonal Bacteraemia — 1 report (12.5%)
8. Pseudomonas Infection — 1 report (12.5%)

Source database →

Frequently asked questions

Is bolus+infusion approved in United States?

bolus+infusion does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for bolus+infusion in United States?

Università degli Studi di Ferrara is the originator. The local marketing authorisation holder may differ — check the official source linked above.